Skip to main content
SpringerLink
Log in

Kurzwirksame Insuline — Neuentwicklungen hin zu mehr Flexibilität für den Patienten

Fast-acting insulin — new developments towards more flexibility for the patient

  • Published:
MMW - Fortschritte der Medizin Aims and scope

Zusammenfassung

Hintergrund

Die Insulinfreisetzung nach den Mahlzeiten erfolgt unter physiologischen Bedingungen sehr schnell und in adäquaten Konzentrationen. Bei Menschen mit Typ-2-Diabetes ist dieser Mechanismus gestört und postprandiale Glukoselevel können stark ansteigen. Um den physiologischen Bedingungen nahezukommen und postprandiale Hyperglykämien zu vermeiden, sollten exogen applizierte Insuline bzw. Insulinanaloga möglichst schnell absorbiert werden und in kurzer Zeit maximale Wirkspiegel erreichen.

Methode

Übersichtsarbeit

Ergebnisse und Schlussfolgerungen

Die Verbesserung der pharmakokinetischen und pharmakodynamischen Eigenschaften von Bolusinsulin-Präparaten steht im Fokus neuer Entwicklungsprojekte. Neben neuen pharmazeutischen Formulierungen wurden auch unterschiedliche Applikationsformen und -orte untersucht. Neueste Entwicklungen hin zu noch schneller wirksamen Insulinen können den Patienten neben einer verbesserten postprandialen Blutzuckerkontrolle auch mehr Flexibilität hinsichtlich der Mahlzeitenplanung bieten.

Abstract

Background

Post-prandial insulin secretion occurs under physiological conditions very fast and in adequate concentrations. This mechanism is impaired in patients with type 2 diabetes and severe increases of postprandial glucose levels may occur. In order to achieve physiological conditions and to avoid postprandial hyperglycemia, exogenous insulin and insulin analogues should be absorbed very fast and appropriate maximum concentrations should be reached very quickly.

Method

Overview

Results and conclusions

The development of new bolus insulins is focused on improved pharmacokinetic and pharmacodynamic properties. Not only new pharmaceutical formulations, but also different application sites and systems have been investigated. The latest innovations resulted in even faster acting insulins, which may offer patients improved postprandial glucose control and greater flexibility regarding meal planning.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Polonsky KS, Given BD, Van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 1988; 81(2): 442–448.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Monnier L, Colette C, Boniface H. Contribution of postprandial glucose to chronic hyperglycaemia: from the “glucose triad” to the trilogy of “sevens”. Diabetes Metab 2006; 32(Spec No2): 2s11–16.

    PubMed  Google Scholar 

  3. Siegelaar SE, Holleman F, Hoekstra JB, DeVries JH. Glucose variability; does it matter? Endocr Rev 2010; 31(2): 171–182.

    Article  CAS  PubMed  Google Scholar 

  4. de Vegt F, Dekker JM, Ruhe HG, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999; 42(8): 926–931.

    Article  PubMed  Google Scholar 

  5. Mane K, Chaluvaraju K, Niranjan M, Zaranappa T, Manjuthej T. Review of insulin and its analogues in diabetes mellitus. J Basic Clin Pharm 2012; 3(2): 283–293.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Krasner A, Pohl R, Simms P, Pichotta P, Hauser R, DE Souza E. A review of a family of ultra-rapid-acting insulins: formulation development. J Diabetes Sci Technol 2012; 6(4): 786–796.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Kildegaard J, Refsgaard HHF, Olsen HB, Jeppesen CB, Ludvigsen S, Sturis J, Ribel U. Probing the mode of action of nicotinaminde in faster-acting insulin aspart: is local s.c. blood-flow affected? Abstract: ADA; 2015.

    Google Scholar 

  8. Buckley ST JC, Olsen HB, Hostrup S, Sturis J. Faster-acting insulin aspart: towards an understanding of the mechanism(s) of action of nicotinamide. Abstract 1024-P: ADA; 2015.

    Google Scholar 

  9. Heise T, Hovelmann U, Brøndsted L, Adrian CL, Nosek L, Haahr H. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes Metab 2015; 17(7): 682–688.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Bookbinder LH, Hofer A, Haller MF, et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 2006; 114(2): 230–241.

    Article  CAS  PubMed  Google Scholar 

  11. Hompesch M, Muchmore DB, Morrow L, Vaughn DE. Accelerated insulin pharmacokinetics and im- proved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase. Diabetes Care 2011; 34(3): 666–668.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Vaughn DE, Yocum RC, Muchmore DB, Sugarman BJ, Vick AM, Bilinsky IP, Frost GI. Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase. Diabetes Technol Ther 2009; 11(6): 345–352.

    Article  CAS  PubMed  Google Scholar 

  13. Muchmore DB, Vaughn DE. Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase. J Diabetes Sci Technol 2012; 6(4): 764–772.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Hompesch M, Muchmore DB, Morrow L, Ludington E, Vaughn DE. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase. Diabetes Technol Ther 2012; 14(3): 218–224.

    Article  CAS  PubMed  Google Scholar 

  15. Vaughn DE, Muchmore DB. Use of recombinant human hyaluronidase to accelerate rapid insulin analogue absorption: experience with subcutaneous injection and continuous infusion. Endocr Pract 2011; 17(6): 914–921.

    Article  PubMed  Google Scholar 

  16. Cengiz E, Weinzimer SA, Sherr JL, et al. Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. Pediatric diabetes 2013; 14(3): 168–173.

    CAS  PubMed  Google Scholar 

  17. Raz I, Weiss R, Yegorchikov Y, Bitton G, Nagar R, Pesach B. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. Clin Ther 2009; 31(5): 980–987.

    Article  CAS  PubMed  Google Scholar 

  18. Sarno MJ, Bell J, Edelman SV. Pharmacokinetics and glucodynamics of rapid-, short-, and intermediate-acting insulins: comparison of jet injection to needle syringe. Diabetes Technol Ther 2002; 4(6): 863–866.

    Article  CAS  PubMed  Google Scholar 

  19. Engwerda EE, Abbink EJ, Tack CJ, de Galan BE. Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology. Diabetes Care 2011; 34(8): 1804–1808.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Edsberg B, Herly D, Hildebrandt P, Kuhl C. Insulin bolus given by sprinkler needle: effect on absorption and glycaemic response to a meal. Br Med J (Clin Res Ed) 1987; 294(6584): 1373–1376.

    Article  CAS  Google Scholar 

  21. Gupta J, Felner EI, Prausnitz MR. Rapid pharmacokinetics of intradermal insulin administered using microneedles in type 1 diabetes subjects. Diabetes Technol Ther 2011; 13(4): 451–456.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Pettis RJ, Ginsberg B, Hirsch L, et al. Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. Diabetes Technol Ther 2011; 13(4): 435–442.

    Article  CAS  PubMed  Google Scholar 

  23. Harvey AJ, Kaestner SA, Sutter DE, Harvey NG, Mikszta JA, Pettis RJ. Microneedle-based intradermal delivery enables rapid lymphatic uptake and distribution of protein drugs. Pharm Res 2011; 28(1): 107–116.

    Article  CAS  PubMed  Google Scholar 

  24. Pettis RJ, Hirsch L, Kapitza C, et al. Microneedle- based intradermal versus subcutaneous administration of regular human insulin or insulin lispro: pharmacokinetics and postprandial glycemic excursions in patients with type 1 diabetes. Diabetes Technol Ther 2011; 13(4): 443–450.

    Article  PubMed  Google Scholar 

  25. Liebl A, Hoogma R, Renard E, et al. A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion. Diabetes Obes Metab 2009; 11(11): 1001–1008.

    Article  CAS  PubMed  Google Scholar 

  26. Heinemann L, Muchmore DB. Ultrafast-acting insulins: state of the art. J Diabetes Sci Technol 2012; 6(4): 728–742.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Fisher JN, Shahshahani MN, Kitabchi AE. Diabetic ketoacidosis: low-dose insulin therapy by various routes. New Engl J Med 1977; 297(5): 238–241.

    Article  CAS  PubMed  Google Scholar 

  28. Thow JC, Johnson AB, Fulcher G, Home PD. Different absorption of isophane (NPH) insulin from subcutaneous and intramuscular sites suggests a need to reassess recommended insulin injection technique. Diabet Med 1990; 7(7): 600–602.

    Article  CAS  PubMed  Google Scholar 

  29. Pfutzner A, Forst T. Pulmonary insulin delivery by means of the Technosphere drug carrier mechanism. Expert Opin Drug Deliv 2005; 2(6): 1097–1106.

    Article  PubMed  Google Scholar 

  30. Rosenstock J, Lorber DL, Gnudi L, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet (London, England) 2010; 375(9733): 2244–2253.

    Article  CAS  Google Scholar 

  31. Morrow L, Muchmore DB, Ludington EA, Vaughn DE, Hompesch M. Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers. Diabetes Technol Ther 2011; 13(10): 1039–1045.

    Article  CAS  PubMed  Google Scholar 

  32. Steiner S, Hompesch M, Pohl R, et al. A novel insulin formulation with a more rapid onset of action. Diabetologia 2008; 51(9): 1602–1606.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Heinemann L, Nosek L, Flacke F, et al. U-100, pH-Neutral formulation of VIAject(®): faster onset of action than insulin lispro in patients with type 1 diabetes. Diabetes Obes Metab 2012; 14(3): 222–227.

    Article  CAS  PubMed  Google Scholar 

  34. Rave K, Heise T, Heinemann L, Boss AH. Inhaled Technosphere insulin in comparison to subcutaneous regular human insulin: time action profile and variability in subjects with type 2 diabetes. J Diabetes Sci Technol 2008; 2(2): 205–212.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Rave K, Potocka E, Heinemann L, et al. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metabol 2009; 11(7): 715–720.

    Article  CAS  Google Scholar 

  36. Luzio SD, Dunseath G, Lockett A, Broke-Smith TP, New RR, Owens DR. The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes. Diabetes Obes Metabol 2010; 12(1): 82–87.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizin/Angiologie/Rehabilitationswesen/Sportmedizin/Diabetologe DDG/Sozialmedizin, Deegenbergklinik und Saale Klinik ( DRV-Bund), Bad Kissingen, Deutschland

    Gerhard W. Schmeisl

  2. Medical Affairs Diabetes, Novo Nordisk Pharma GmbH, Mainz, Deutschland

    Yasmin Kretzschmar

  3. Facharzt für Innere Medizin / Angiologie / Rehabilitationswesen / Sportmedizin / Diabetologe DDG / Sozialmedizin Deegenbergklinik, Burgstraße, 97688, Bad Kissingen, Deutschland

    Gerhard W. Schmeisl

Authors
  1. Gerhard W. Schmeisl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yasmin Kretzschmar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gerhard W. Schmeisl.

Additional information

This article is part of a supplement not sponsored by the industry.

Interessenkonflikt

Dr. Gerhard-W. Schmeisl erklärt, dass bezüglich dieses Artikels kein Interessenkonflikt besteht. Für das Verfassen dieses Manuskriptes wurde den Autoren kein Honorar gezahlt. Dr. Yasmin Kretzschmar ist angestellt bei der Firma Novo Nordisk Pharma GmbH, Mainz.

Wir danken Frau Dr. Anika Burkard für die redaktionelle Mitarbeit. Frau Dr. Burkard erklärt, dass ihre Firma 3K Agentur für Kommunikation GmbH, diesbezüglich eine inhaltlich ungebundene Unterstützung von der Firma Novo Nordisk Pharma GmbH, D-55127 Mainz, erhalten hat.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schmeisl, G.W., Kretzschmar, Y. Kurzwirksame Insuline — Neuentwicklungen hin zu mehr Flexibilität für den Patienten. MMW - Fortschritte der Medizin 158 (Suppl 6), 5–11 (2016). https://doi.org/10.1007/s15006-016-9053-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-016-9053-8

Schlüsselwörter

Keywords

Search

Navigation